Efficacy of High-Dose Atorvastatin Loading in Patients With ST-Elevation Myocardial Infarction (STEMI) Undergoing

Mansi Yadav1, Archana Dhami2, Umar Ahsan3

  • 1Internal Medicine, Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, IND.

Cureus
|September 24, 2025
PubMed

Insights

High-dose atorvastatin loading in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary PCI shows promise. It reduces no-reflow and inflammation but needs more research for hard clinical outcomes.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • ST-segment elevation myocardial infarction (STEMI) is a major cause of death.
  • Primary percutaneous coronary intervention (PCI) has improved outcomes.
  • High-dose statin loading is a potential cardioprotective strategy.

Purpose of the Study:

  • To systematically review randomized controlled trials on high-dose atorvastatin loading in STEMI patients undergoing primary PCI.
  • To evaluate the efficacy and safety of this strategy.

Main Methods:

  • Systematic review of randomized controlled trials.
  • Literature search across PubMed, Embase, Cochrane Library, and Scopus.
  • Inclusion of 5 trials with 559 patients comparing 80 mg atorvastatin loading versus standard/no loading.

Main Results:

  • Significant reduction in the no-reflow phenomenon and improved angiographic outcomes (myocardial blush grade, corrected TIMI frame count).
  • Consistent reduction in inflammatory markers (hs-CRP, IL-6) and improved endothelial function.
  • Inconsistent results for hard clinical endpoints (MACE); reassuring safety profile with no increased adverse events.

Conclusions:

  • High-dose atorvastatin loading demonstrates mechanistic benefits in STEMI patients undergoing primary PCI.
  • Further large-scale trials with standardized protocols and long-term follow-up are necessary.
  • Optimal dosing and patient selection require further investigation.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
321
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
220
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
215
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
237
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
812